Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 16/20 | 0.82 |
| ▸ | CYP11B2 | P19099 | 16/20 | 0.82 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3079356 | 0.86 | CYP11B1 (0.71) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL9570444 | 0.83 | CYP11B1 (0.68) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL8971686 | 0.83 | CYP11B1 (0.68) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL9092547 | 0.83 | CYP11B1 (0.73) | CYP11B1CYP11B2IDO1 | |
| SCHEMBL2104118 | 0.81 | CYP11B1 (0.64) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL531371 | 0.81 | CYP11B1 (0.73) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL6776413 | 0.80 | CYP11B1 (0.85) | CYP11B1CYP11B2 | |
| SCHEMBL9092962 | 0.80 | CYP11B1 (0.72) | CYP11B1CYP11B2IDO1 | |
| SCHEMBL9641631 | 0.80 | CYP11B1 (0.62) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL6748340 | 0.79 | CYP11B1 (0.62) | CYP11B1CYP11B2IDO1HPGDSP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171844-A1 | Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase | LEONARD DANIELE MARIE (US) | 2004-09-02 | — | — | US | disclosed |
| US-20030232790-A1 | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase | WARNER-LAMBERT COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1276724-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079179-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| US-5648368-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0673247-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0673247-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994012181-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5270322-A | Imidazo[1,2-a]pyridines, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1993-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171844-A1 | Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase | NRAS, HRAS, FNTB | CYP11B1 507/4885CYP11B2 1099/4885IDO1 2705/4885 |
| US-20030232790-A1 | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase | NRAS, FNTA, CYP46A1 | CYP11B1 206/4885CYP11B2 430/4885IDO1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.